← Leaderboards
Karen G. Anthony
L2 Diagnostics, Llc
$11,228,942
Attributed
$12,637,777
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2006–25$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,637,777 · 11
By mechanism
U01$7,021,452 · 1
R44$2,470,389 · 2
R43$1,946,725 · 6
R41$599,740 · 1
N43$599,471 · 1
Top collaborators
- Pier Francesco Cirillo3 shared
- Vinod Satisch Ramgolam2 shared
- Alan Gordon Sutherland2 shared
- Sahar Usmani-Brown1 shared
Most similar at L2 Diagnostics, Llc
Same institution · by research overlap
- Pier Francesco Cirillo$740,795
- Alan Gordon Sutherland$2,685,002
- Vinod Satisch Ramgolam$669,015
- Yu-Min Chuang$599,598
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelTimelinePharmaceutical PreparationsInhibitor/AntagonistSmall MoleculeLeadPre-ClinicalAnimal ModelPharmaceutical ChemistryEfficacy EvaluationFuturePathway InteractionsVisionPharmacologic SubstanceIn VivoBiologicalEnzymesMigration Inhibitory FactorPreventAreaResponseCytokineIn VitroInterest
Grant awards (21)
Therapeutic vaccine platform to boost immune responses in Tuberculosis$599,471
N43 · FY2025 · AI · contact PI
Delivery of a candidate AgTRIOVx malaria vaccine by thermostable microneedle patches$299,862
R41 · FY2025 · AI · contact PI
Delivery of a candidate AgTRIOVx malaria vaccine by thermostable microneedle patches$299,878
R41 · FY2024 · AI · contact PI
Development of A Narrow Spectrum Anti-Tubercular Agent$285,676
R43 · FY2020 · AI · contact PI
Development of A Narrow Spectrum Anti-Tubercular Agent$299,661
R43 · FY2019 · AI · contact PI
Therapeutic Inhibition of MIF to Improve Glucocorticoid Response$154,035
R43 · FY2019 · AI · contact PI
Therapeutic Inhibition of MIF to Improve Glucocorticoid Response$299,407
R43 · FY2018 · AI · contact PI
Allosteric MIF Inhibitors for Rheumatoid Arthritis Therapy$780,982
R44 · FY2017 · AR · contact PI
Allosteric MIF Inhibitors for Rheumatoid Arthritis Therapy$6,092
R44 · FY2017 · AR · contact PI
Allosteric MIF Inhibitors for Rheumatoid Arthritis Therapy$694,516
R44 · FY2016 · AR · contact PI
Therapeutic Inhibition of MIF in Type 1 Diabetes$297,302
R43 · FY2015 · DK
Broad-Spectrum Antimicrobials Targeting the D-Alanine Pathway$1,605,387
U01 · FY2013 · AI · contact PI
Therapeutic Inhibition of MIF in Rheumatoid Arthritis$436,903
R44 · FY2013 · AR · contact PI
Broad-Spectrum Antimicrobials Targeting the D-Alanine Pathway$1,655,184
U01 · FY2012 · AI · contact PI
Therapeutic Inhibition of MIF in Rheumatoid Arthritis$551,896
R44 · FY2012 · AR · contact PI
Broad-Spectrum Antimicrobials Targeting the D-Alanine Pathway$1,619,778
U01 · FY2011 · AI · contact PI
Broad-Spectrum Antimicrobials Targeting the D-Alanine Pathway$989,745
U01 · FY2010 · AI · contact PI
Broad-Spectrum Antimicrobials Targeting the D-Alanine Pathway$1,151,358
U01 · FY2009 · AI · contact PI
Therapeutic Inhibition of MIF in Rheumatoid Arthritis$239,686
R43 · FY2009 · AR · contact PI
Small Molecule West Nile Virus Inhibitors$200,994
R43 · FY2008 · AI · contact PI
Small Molecule Alanine Racemase Inhibitors as Novel Therapeutics for Tuberculosis$169,964
R43 · FY2006 · AI · contact PI